Skip to main content
. 2006 Oct;90(10):1316–1321. doi: 10.1136/bjo.2006.095190

graphic file with name bj95190.f2.jpg

Figure 2 Toxicity determination using the Life/Dead viability/cytotoxicity assay. (A) RGC5 cells and bevacizumab 2.5 mg/ml after 48 hours of incubation. (B) RGC5 cells: negative control. (C) RGC5 cells cytotoxic control: treatment with Triton X‐100. (D) ARPE19 cells and bevacizumab 0.25 mg/ml. (E) ARPE19 cells and bevacizumab 2.5 mg/ml: showing a decreased number of viable ARPE19 cells after 2 days of incubation. (F) negative control (magnification ×200).